ATHE Live signals | Maximize Profits with Getagraph.com

BUY 93737 min ago

@ $1.920

Issued: 14 Feb 2024 @ 15:33

Return: 6.25%

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	53 503.00
Average Volume	80 835.00
Market Cap	16.73M
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.070
ATR14	$0.0250 (1.23%)

Volume Correlation

Long: 0.05 (neutral)

Short: -0.09 (neutral)

Signal:(46.339) Neutral

Alterity Therapeutics Correlation

10 Most Positive Correlations
ZYXI	0.892
HAS	0.882
SNES	0.88
RUBY	0.876
PASG	0.875
SRTS	0.874
INTZ	0.872
SIGA	0.868
VNET	0.867
GETVV	0.867

10 Most Negative Correlations
PLUS	-0.896
VCTR	-0.885
LOVE	-0.88
CRWD	-0.867
RDUS	-0.861
SHSP	-0.857
TVTY	-0.855
ZGNX	-0.852
TRNS	-0.847
PAE	-0.839

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Alterity Therapeutics Correlation - Currency/Commodity

-0.43
( neutral )

-0.28
( neutral )

0.00
( neutral )

0.19
( neutral )

-0.55
( weak negative )

0.26
( neutral )

Alterity Therapeutics Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.00570

Q2	2023
Revenue:	$812 117
Gross Profit:	$757 643 (93.29 %)
EPS:	$-0.00110

Q1	2023
Revenue:	$762 980
Gross Profit:	$711 802 (93.29 %)
EPS:	$-0.00110

Q4	2022
Revenue:	$954 269
Gross Profit:	$899 461 (94.26 %)
EPS:	$-0.000900

Financial Reports:

No articles found.

Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.